Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organisation (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...

Lenacapavir is the first injectable pre-exposure prophylaxis product that only needs to be taken twice a year. It offers a ...

New World Health Organisation (WHO) recommendations for the use of long-acting HIV prevention and treatment are a welcome boost in the global efforts to end ...

Lenacapavir, a long-acting injectable pre-exposure prophylaxis, has been recommended by the WHO to help protect high-risk ...

The World Health Organization (WHO) has officially recommended the use of lenacapavir, a twice-yearly injectable pre-exposure ...

Health leaders at the International AIDS Society (IAS) 2025 conference in Kigali have warned that shrinking funding and ...